Protracted Results of Dose-Intensive Therapy using Cyclophosphamide, Carmustine, and Continuous Infusion Etoposide with Autologous Stem Cell Support in Patients with Relapse or Refractory Hodgkin's Disease: A Phase II Study from the North American Marrow Transplant Group

References

• Gribben J. G., Goldstone A. H., Linch D. C., Taghipour G., et al. Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional dose chemotherapy. J Clin Oncol 1989; 7: 1621
   PubMed Web of Science ®Google Scholar
• Reece D. E., Connors J. M., Spinelli J. J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide, +/- cisplatinum, and autologous bone marrow transplantation for Hodgkin's Disease in first remission after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Chopra R., McMillan A. K., Linch D. C., et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's Disease a single-center. eight year study of 155 patients. Blood 1993; 81: 1137–1145
   Google Scholar
• Reece D. E., Barnett M. J., Shepherd J. D., et al. High-dose cyclophosphamide; carmustine (BCNU), and etoposide (VP16–213) with or without cisplatinum (CBV +/-P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451–456
   PubMed Web of Science ®Google Scholar
• Reece D. E., Barnett M. J., Connors J. M., et al. Intensive chemotherapy with cyclophosphamide. carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol. 1991; 9: 1871–1879
   Google Scholar
• Jagannath S., Annitage J. O., Dicke K. A., et al. Prognostic factors for response and survival after highdose cyclophosphamide, carmustine. and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's Disease. J. Clin Oncol 1989; 7: 179–185
   Google Scholar
• Wheeler C., Antin J. H., Churchill W. H., Come S. E., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648–656
   PubMed Web of Science ®Google Scholar
• Demirer T., Weaver C. H., Buckner C. D., et al. High-dose, cyclophosphamide, carmustine, and etoposide, followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596–602
   PubMed Web of Science ®Google Scholar
• Nademanee A., O'Donnell M. R., Snyder D. S., et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow andor peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's Disease: results in 85 patients with analysis of prognostic factors. Blood. 1995; 85: 1381–1390
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 157–181
   Web of Science ®Google Scholar
• SPSS. SPSS Statistical Software Releasc. Chicago. 1993
   Google Scholar
• StatXact 3 for Windows, CYTEL Software Corporation. 1996, Cambridge, MA
   Google Scholar
• Homing S. J., Chao J. N., Negrin R. S., et al. The Standford experience with high-dose etoposide cytoreductive regimen-and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol 1991; 2(Suppl 1)45–50
   Google Scholar
• Phillips G. L., Wolff S. N., Henig R. H., et al. Treatment of progressive Hodgkin's disease with intensive chemo-radiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086–2092
   PubMed Web of Science ®Google Scholar
• Jones R. J., F'iantadosi S., Mann R. B., et al. High-dose cytotoxic therapy and Hodgkin's disease. J Clin Oncol 1990; 8: 527–537
   PubMed Web of Science ®Google Scholar
• Henig R. H. Highdose etoposide and marrow transplantation. Cancer 1991; 67: 292–298
   PubMed Web of Science ®Google Scholar
• Champlin R. Bone marrow transplantation for Hodgkin's Disease: Recent advances and current issues. Leuk Lymphoma 1993; 10(Suppl)103–108
   PubMedGoogle Scholar
• Phillips G. L., Reece D. E., Barnett M. J., et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 1989; 7: 1039–1045
   PubMed Web of Science ®Google Scholar
• Milipied N., Fielding A. K., Pearce R. M., et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's Disease. European group for blood and marrow transplantation. J Clin Oncol 1996; 14: 1291–1296
   PubMed Web of Science ®Google Scholar
• Taylor K., Jagannath S., Spitzer G. Recombinant human granulocyte-stimulating factor hastens granulocyte recover after highdose chemotherapy and autologous bone marrow transplantation in Hodgkin's Disease. J Clin Oncol 1989; 7: 1791–1799
   PubMed Web of Science ®Google Scholar
• Peters W. P. Comparative effects of granulocyte-mac-rophage colony stimulating factor (GM-CSF) and granulo-cyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
   PubMed Web of Science ®Google Scholar
• Schmitz N., Dreger P., Zander A. R., et al. Randomized, controlled multicentre study of recombinant granulo-cyte colony-stimulating factor (filigrastim) in patients with Hodgkin's Disease and non-Hodgkin's Disease lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261–265
   PubMed Web of Science ®Google Scholar
• Blume K. G., Forman J. J. High-dose etoposide (VP-16) containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 1992; 19(Suppl 13)63–66
   PubMed Web of Science ®Google Scholar
• Henig R. H., Lynch J., Christiansen N. P., et al. Dose-intensive chemotherapy with etoposide-cyclophospha-mide for advanced breast cancer. Semin Oncol 1996; 23: 28–32
   Web of Science ®Google Scholar
• Urba W. J., Wilson W. H., Duffey P. L., et al. Recent National Cancer Institute lymphoma trials of etoposide-con-taining combination chemotherapy. Semin Oncol 1992; 19(Supp 13)26–32
   PubMed Web of Science ®Google Scholar
• Aisner J., Lee E. J. Etoposide: Current and future status. Cancer 1991; 67: 215–219
   PubMed Web of Science ®Google Scholar
• Mross K., Bewermeier P., Reifke J., et al. Pharma-cokinetics of high-dose VP-16: &hour infusion versus 34-hour infusion. Bone Marrow Transplant 1994; 13: 423–430
   PubMed Web of Science ®Google Scholar
• Korbling M., Holle R., Haas R., et al. Autologous blood stem cell transplantation in patients with advanced Hodgkin's Disease and prior radiation to the pelvic site. J Clin Oncol 1996; 8: 978–985
   Google Scholar
• Champlin R. E. Peripheral blood progenitor cells: A replacement for marrow transplantation. Semin Oncol 1996; 23: 15–21
   PubMed Web of Science ®Google Scholar
• Deeg H. J., Witherspoon R. P. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol Oncol Clin North Am 1993; 7: 417–429
   PubMed Web of Science ®Google Scholar
• Darrington D. L., Vose J. M., Anderson J. R., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol. 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Popat U., Anderson B. S., Van Besien K., et al. ABMT in recurrent or refractory HD: Long term results. Blood. 1997; 90%(Suppl 1 abstr)500
   Google Scholar
• Bieman P. J., Bagin R. G., Jagannath S., et al. High-dose chemotherapy followed by autologous hematopoi-etic rescue in Hodgkin's Disease: long-term follow-up in 128 patients. AM Oncol 1993; 4(9)767–773
   Google Scholar
• Wheeler C., Eickhoff C., Elias A., et al. High-dose cyclophosphamide. carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3: 98–106
   Google Scholar
• Homing S. J., Chao N. J., Negrin R. S., et al. Highdose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Standford University results and prognostic indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Nagler A., Ackersteinm A., Naparstek E., et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients post autologous marrow or stem cell transplantation. Blood 1997; 89: 3951–3959
   PubMed Web of Science ®Google Scholar
• Vey N., Blake D., Tiberghien P., et al. A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leukemia Lymphoma 1996; 21: 107–114
   PubMed Web of Science ®Google Scholar